{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidsyijyrgdmeex7xrpn3eia6i5k4k2323unbrtm47yy75uxswc6vm",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mm6bq7wppdp2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiaugortcho7cp7dfj52epo6qizzg3wazhgr3s5aeewerijooc3pa4"
    },
    "mimeType": "image/jpeg",
    "size": 82700
  },
  "path": "/news/2026-05-fda-expansion-vyvgart-hytrulo-generalized.html",
  "publishedAt": "2026-05-18T20:40:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "The U.S. Food and Drug Administration has approved a label expansion for Vyvgart (efgartigimod alfa-fcab) and Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with  (gMG). The expanded approval was granted to argenx.",
  "title": "FDA approves label expansion for Vyvgart, Vyvgart Hytrulo for generalized myasthenia gravis"
}